tetano
Editor, Senior Moderator
Emerg Infect Dis
. 2021 Sep 27;27(11).
doi: 10.3201/eid2711.211886. Online ahead of print.
Effectiveness of BNT162b2 Vaccine in Adolescents during Outbreak of SARS-CoV-2 Delta Variant Infection, Israel, 2021
Aharona Glatman-Freedman, Yael Hershkovitz, Zalman Kaufman, Rita Dichtiar, Lital Keinan-Boker, Michal Bromberg
Abstract
In Israel, the BNT162b2 vaccine against severe acute respiratory syndrome coronavirus 2 was approved for use in adolescents in June 2021, shortly before an outbreak of B.1.617.2 (Delta) variant-dominant infection. We evaluated short-term vaccine effectiveness and found the vaccine to be highly effective among this population in this setting.
Keywords: 2019 novel coronavirus disease; COVID-19; Delta variant; Israel; SARS-CoV-2; adolescents; coronavirus disease; respiratory infections; severe acute respiratory syndrome coronavirus 2; vaccine effectiveness; viruses; zoonoses.
. 2021 Sep 27;27(11).
doi: 10.3201/eid2711.211886. Online ahead of print.
Effectiveness of BNT162b2 Vaccine in Adolescents during Outbreak of SARS-CoV-2 Delta Variant Infection, Israel, 2021
Aharona Glatman-Freedman, Yael Hershkovitz, Zalman Kaufman, Rita Dichtiar, Lital Keinan-Boker, Michal Bromberg
- PMID: 34570694
- DOI: 10.3201/eid2711.211886
Abstract
In Israel, the BNT162b2 vaccine against severe acute respiratory syndrome coronavirus 2 was approved for use in adolescents in June 2021, shortly before an outbreak of B.1.617.2 (Delta) variant-dominant infection. We evaluated short-term vaccine effectiveness and found the vaccine to be highly effective among this population in this setting.
Keywords: 2019 novel coronavirus disease; COVID-19; Delta variant; Israel; SARS-CoV-2; adolescents; coronavirus disease; respiratory infections; severe acute respiratory syndrome coronavirus 2; vaccine effectiveness; viruses; zoonoses.